Visit https://www.peervoice.com/HGH860 to view the entire programme with slides. After completing “Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC”, participants will be able to: Apply current evidence-based treatment guidelines in patients with molecular biomarker–positive non–small-cell lung cancer (NSCLC); Propose personalised treatment plans for patients with molecular biomarker–positive NSCLC; and Identify key clinical challenges encountered in the treatment of NSCLC, including next steps in patients without targetable driver mutations.

Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/GBR860 to view the entire programme with slides. After completing “Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) - Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?”, participants will be able to: Evaluate the efficacy and safety evidence for recommended interventions to manage type 2 diabetes (T2D) in children and adolescents; Describe age-, disease-, and treatment-related considerations which impact decision-making in the treatment of T2D in children and adolescents; and Propose evidence-based, guideline-recommended management plans for children and adolescents with T2D.

Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) - Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?

Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Visit https://www.peervoice.com/GYE860 to view the entire programme with slides. After completing “Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics”, participants will be able to: Assess available safety and efficacy data from randomised clinical trials evaluating first- and next-generation FLT3 inhibitors in acute myeloid leukaemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilising recommended dose schedules; and Formulate adverse event management strategies for patients with newly diagnosed FLT3-mutant AML receiving a FLT3 inhibitor, including monitoring and supportive treatment.

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

Download our free app to listen on your phone